Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

NCT06744686 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: HT-102
DRUG: HT-102
DRUG: Placebo

Sponsor

Suzhou HepaThera Biotech Co., Ltd.